By Steve Kardell | Published October 19, 2017 | Posted in Whistleblower Litigation | Tagged Tags: FCA claims, Medicaid, misclassified EpiPen |
Sanofi-Aventis, a large pharmaceutical company, was awarded $38.7 million for its role in bringing a $465 million False Claims Act case against Mylan. The company settled amid allegations that it knowingly misclassified EpiPen as a generic drug so it could avoid paying back the rebates it owed to Medicaid. The lawsuit was initially filed under Read More
Read More